ClinicalTrials.gg
CompletedNCT04028492Updated Sep 24, 2026Results posted

Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis

A Phase 3 interventional study of Tradipitant and Placebo in Idiopathic Gastroparesis, Diabetic Gastroparesis and Gastroparesis, sponsored by Vanda Pharmaceuticals. Completed at 36 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
979
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 184 studies in Gastroparesis with a site in United States — 33 open to participants now, 41 under way, 2 of them phase 3. Gastroparesis · United States.

Enrollment
Largest of 136
979 · median 36
Started
2019
with 16 others
Phase 3
12 of 184
none open now
Registered
109th of 184
by date

Among the 184 studies in Gastroparesis with a site in United States, this one has the largest enrollment of the 136 interventional ones that give a count, is one of 17 that started in 2019, is one of 12 in phase 3, and was the 109th registered.

Gastroparesis

323 studies on the registry are indexed under Gastroparesis; 75 are open to participants now.

Browse Gastroparesis studies →

Open to participants now

33 of the 184 studies in Gastroparesis with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Gastroparesis studies recruiting now, 25 (51%) set no upper age limit and 14 (29%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 184 studies in Gastroparesis with a site in United States, or all of them as a file.
02

Study summary

To investigate the safety and efficacy of tradipitant versus placebo in relieving nausea and other symptoms of gastroparesis.

03

Conditions studied

  • Idiopathic Gastroparesis
  • Diabetic Gastroparesis
  • Gastroparesis

Keywords

  • gastroparesis
  • idiopathic
  • diabetic
  • tradipitant
  • nausea
  • vomiting
  • stomach
  • motility
  • functional
  • NK-1 antagonist
  • neurokinin 1 receptor
  • substance p
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with gastroparesis
  • Demonstrated delayed gastric emptying
  • Presence of moderate to severe nausea
  • (BMI) of ≥18 and ≤40 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Another active disorder or treatment which could explain or contribute to symptoms of gastroparesis
  • A positive test for drugs of abuse at the screening or evaluation visits;
  • Exposure to any medication in the past 60 days
  • Gastrectomy, fundoplication, vagotomy, pyloroplasty, bariatric surgery, or gastric stimulation device surgically implanted within the last year
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
979 participants (actual)

Study arms

  • Experimental
    Tradipitant

    Oral Capsule

    Drug: Tradipitant

  • Placebo comparator
    Placebo

    Oral Capsule

    Drug: Placebo

  • Experimental
    Open Label Tradipitant

    Oral Capsule

    Drug: Open Label Tradipitant

Interventions

  • BID

  • DrugPlacebo

    BID

  • DrugOpen Label Tradipitant

    BID

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in the Biweekly Average of Daily Nausea Severity Score Using MMRM Model ITT Population

    The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients to rate the worst occurrence of each cardinal symptom of gastroparesis (nausea severity, early satiety, postprandial fullness, bloating, and abdominal pain) in the past 24 hours on a Likert scale from 0 (no symptoms) to 5 (very severe). Change from baseline in average nausea severity score is calculated as the biweekly average post value minus baseline value of the daily nausea severity score from the GCSDD. A negative change indicates improvement.

    Time frame: 12 weeks

Secondary outcomes

  1. Change From Baseline in Gastroparesis Cardinal Symptom Index (GCSI) Total Score Using MMRM Model ITT Population

    The GCSI is a subject reported outcome administered in-clinic with a 2-week recall period to measure the severity of symptoms in gastroparesis. The GCSI is composed of 9 items based on three subscales: post-prandial fullness/early satiety (4 items); nausea/vomiting (3 items), and bloating (2 items). The severity of each symptom is rated on a six-point Likert response scale. The minimal scale value = 0 (none) and the maximum scale value = 5 (very severe). GCSI Total score is constructed as the average of the three symptom sub-scales. Higher score is indicative of greater symptom severity.

    Time frame: 12 Weeks

  2. Change From Baseline to Week 12 in the Biweekly Percentage of Nausea Free Days Using MMRM Model ITT Population

    The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients if they have had any nausea over the past 24 hours and if yes, to rate the worst occurrence in the past 24 hours on a Likert scale from 1 (very mild) to 5 (very severe). Change in weekly percentage of nausea-free days from baseline is calculated as biweekly average post value minus baseline value.

    Time frame: 12 Weeks

  3. Change From Baseline in Overall Patient Benefit Scale (OPBS) ITT Population

    The Overall Patient Benefit Scale (OPBS) is a weighted average of the recoded symptom improvement score of the five PRCGS items. The PRCGS data are recoded as follows: 3 - very much improved, 2 - much improved, 1 - minimally improved, 0 - no change or worse. The OPBS ranges from 0 to 3, with higher values indicating a better outcome.

    Time frame: 12 Weeks

07

Results

Posted Sep 24, 2026

Participant flow

Participant flow — Overall Study
MilestoneTradipitantPlaceboOpen Label Tradipitant
Started10299778
Completed8388643
Not completed1911135

Outcome measures

PrimaryChange From Baseline to Week 12 in the Biweekly Average of Daily Nausea Severity Score Using MMRM Model ITT Population

The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients to rate the worst occurrence of each cardinal symptom of gastroparesis (nausea severity, early satiety, postprandial fullness, bloating, and abdominal pain) in the past 24 hours on a Likert scale from 0 (no symptoms) to 5 (very severe). Change from baseline in average nausea severity score is calculated as the biweekly average post value minus baseline value of the daily nausea severity score from the GCSDD. A negative change indicates improvement.

Time frame:
12 weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in the Biweekly Average of Daily Nausea Severity Score Using MMRM Model ITT Population
score on a scaleTradipitantPlacebo
Change From Baseline to Week 12 in the Biweekly Average of Daily Nausea Severity Score Using MMRM Model ITT Population-1.55 (-1.82 to -1.29)-1.49 (-1.76 to -1.23)
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = 0.7411 (P value refers to LS mean difference.)
SecondaryChange From Baseline in Gastroparesis Cardinal Symptom Index (GCSI) Total Score Using MMRM Model ITT Population

The GCSI is a subject reported outcome administered in-clinic with a 2-week recall period to measure the severity of symptoms in gastroparesis. The GCSI is composed of 9 items based on three subscales: post-prandial fullness/early satiety (4 items); nausea/vomiting (3 items), and bloating (2 items). The severity of each symptom is rated on a six-point Likert response scale. The minimal scale value = 0 (none) and the maximum scale value = 5 (very severe). GCSI Total score is constructed as the average of the three symptom sub-scales. Higher score is indicative of greater symptom severity.

Time frame:
12 Weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline in Gastroparesis Cardinal Symptom Index (GCSI) Total Score Using MMRM Model ITT Population
score on a scaleTradipitantPlacebo
Change From Baseline in Gastroparesis Cardinal Symptom Index (GCSI) Total Score Using MMRM Model ITT Population-1.48 (-1.72 to -1.23)-1.39 (-1.63 to -1.15)
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = 0.6283 (P value refers to LS Mean Difference.)MMRM Model
SecondaryChange From Baseline to Week 12 in the Biweekly Percentage of Nausea Free Days Using MMRM Model ITT Population

The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients if they have had any nausea over the past 24 hours and if yes, to rate the worst occurrence in the past 24 hours on a Likert scale from 1 (very mild) to 5 (very severe). Change in weekly percentage of nausea-free days from baseline is calculated as biweekly average post value minus baseline value.

Time frame:
12 Weeks
Reported as:
Least squares mean · Percentage of Days
Change From Baseline to Week 12 in the Biweekly Percentage of Nausea Free Days Using MMRM Model ITT Population
Percentage of DaysTradipitantPlacebo
Change From Baseline to Week 12 in the Biweekly Percentage of Nausea Free Days Using MMRM Model ITT Population20.70 (13.08 to 28.32)28.96 (21.37 to 36.55)
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = 0.1312 (P value refers to LS Mean Difference)MMRM Model
SecondaryChange From Baseline in Overall Patient Benefit Scale (OPBS) ITT Population

The Overall Patient Benefit Scale (OPBS) is a weighted average of the recoded symptom improvement score of the five PRCGS items. The PRCGS data are recoded as follows: 3 - very much improved, 2 - much improved, 1 - minimally improved, 0 - no change or worse. The OPBS ranges from 0 to 3, with higher values indicating a better outcome.

Time frame:
12 Weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline in Overall Patient Benefit Scale (OPBS) ITT Population
score on a scaleTradipitantPlacebo
Change From Baseline in Overall Patient Benefit Scale (OPBS) ITT Population1.55 (1.33 to 1.78)1.39 (1.17 to 1.61)
Statistical analysis
  • Tradipitant vs Placebo · Mixed Models Analysis · p = 0.3117 (P value refers to LS mean difference)Mixed Model Repeated Measures
Post-hocChange From Baseline in the Biweekly Average of Daily Nausea Severity Score Using MMRM Model PK Population

The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients to rate the worst occurrence of each cardinal symptom of gastroparesis (nausea severity, early satiety, postprandial fullness, bloating, and abdominal pain) in the past 24 hours on a Likert scale from 0 (no symptoms) to 5 (very severe). Change from baseline in average nausea severity score is calculated as the biweekly average post value minus baseline value of the daily nausea severity score from the GCSDD. A negative change indicates improvement.

Time frame:
12 Weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Biweekly Average of Daily Nausea Severity Score Using MMRM Model PK Population
score on a scaleHigh PK TradipitantPlacebo
Change From Baseline in the Biweekly Average of Daily Nausea Severity Score Using MMRM Model PK Population-1.89 (-2.26 to -1.53)-1.49 (-1.77 to -1.22)
Statistical analysis
  • High PK Tradipitant vs Placebo · Mixed Models Analysis · p = 0.0831 (P value refers to LS mean difference)Mixed Model Repeated Measures
Post-hocChange From Baseline in GCSI Total Score Using MMRM Model PK Population

The GCSI is a subject reported outcome administered in-clinic with a 2-week recall period to measure the severity of symptoms in gastroparesis. The GCSI is composed of 9 items based on three subscales: post-prandial fullness/early satiety (4 items); nausea/vomiting (3 items), and bloating (2 items). The severity of each symptom is rated on a six-point Likert response scale. The minimal scale value = 0 (none) and the maximum scale value = 5 (very severe). GCSI Total score is constructed as the average of the three symptom sub-scales. Higher score is indicative of greater symptom severity.

Time frame:
12 weeks
Reported as:
Least squares mean · score on an scale
Change From Baseline in GCSI Total Score Using MMRM Model PK Population
score on an scaleHigh PK TradipitantPlacebo
Change From Baseline in GCSI Total Score Using MMRM Model PK Population-1.61 (-1.95 to -1.27)-1.39 (-1.64 to -1.13)
Statistical analysis
  • High PK Tradipitant vs Placebo · Mixed Models Analysis · p = 0.3113 (P value refers to LS mean difference)Mixed Model Repeated Measures
Post-hocChange From Baseline to Week 12 in the Biweekly Percentage of Nausea Free Days Using MMRM Model PK Population

The Gastroparesis Core Symptom Daily Diary (GCSDD) is a patient reported diary that asks patients if they have had any nausea over the past 24 hours and if yes, to rate the worst occurrence in the past 24 hours on a Likert scale from 1 (very mild) to 5 (very severe). Change in weekly percentage of nausea-free days from baseline is calculated as biweekly average post value minus baseline value.

Time frame:
12 weeks
Reported as:
Least squares mean · Percentage of Days
Change From Baseline to Week 12 in the Biweekly Percentage of Nausea Free Days Using MMRM Model PK Population
Percentage of DaysHigh PK TradipitantPlacebo
Change From Baseline to Week 12 in the Biweekly Percentage of Nausea Free Days Using MMRM Model PK Population30.31 (19.53 to 41.10)29.11 (21.05 to 37.17)
Statistical analysis
  • High PK Tradipitant vs Placebo · Mixed Models Analysis · p = 0.8599 (P value refers to LS mean difference)Mixed Model Repeated Measures
Post-hocChange From Baseline in Overall Patient Benefit Scale (OPBS) PK Population

The Overall Patient Benefit Scale (OPBS) is a weighted average of the recoded symptom improvement score of the five PRCGS items. The PRCGS data are recoded as follows: 3 - very much improved, 2 - much improved, 1 - minimally improved, 0 - no change or worse. The OPBS ranges from 0 to 3, with higher values indicating a better outcome.

Time frame:
12 Weeks
Reported as:
Least squares mean · score on a scale
Change From Baseline in Overall Patient Benefit Scale (OPBS) PK Population
score on a scaleHigh PK TradipitantPlacebo
Change From Baseline in Overall Patient Benefit Scale (OPBS) PK Population1.70 (1.3944 to 2.0151)1.40 (1.1651 to 1.6285)
Statistical analysis
  • High PK Tradipitant vs Placebo · Mixed Models Analysis · p = 0.1170Mixed Models Repeated Measures

Adverse events

Collected over All Adverse Events (AEs) were collected from the time of the subject's informed consent signature until the end of the subject's study participation. AEs reported or learned up to 7 days after the subject's last study visit were recorded, up to 17 weeks. SAEs reported or learned up to 30 days after last study visit were recorded, up to 20 weeks.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tradipitant0/102 (0%)3/102 (2.9%)48/102 (47.1%)
Placebo0/99 (0%)2/99 (2%)25/99 (25.3%)
Open Label Tradipitant2/778 (0.3%)35/778 (4.5%)267/778 (34.3%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventTradipitantPlaceboOpen Label Tradipitant
Procedural painInjury, poisoning and procedural complications0/1021/990/778
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1021/990/778
HypoglycaemiaMetabolism and nutrition disorders1/1020/990/778
Myocardial infarctionCardiac disorders1/1020/990/778
Small intestinal obstructionGastrointestinal disorders1/1020/991/778
DiverticulitisInfections and infestations0/1020/993/778
Corona virus infectionInfections and infestations0/1020/992/778
ParaesthesiaNervous system disorders0/1020/992/778
CellulitisInfections and infestations0/1020/992/778
HypoglycaemiaMetabolism and nutrition disorders0/1020/992/778
Most frequent other events
Showing 10 of 19
Most frequent other events
EventTradipitantPlaceboOpen Label Tradipitant
DiarrhoeaGastrointestinal disorders10/1022/9937/778
Urinary tract infectionInfections and infestations4/1024/9920/778
HeadacheNervous system disorders4/1022/9922/778
ConstipationGastrointestinal disorders1/1023/9913/778
DizzinessNervous system disorders3/1023/9917/778
NauseaGastrointestinal disorders2/1022/9923/778
FatigueGeneral disorders2/1021/9923/778
SinusitisInfections and infestations3/1021/998/778
PneumoniaInfections and infestations3/1020/994/778
Corona virus infectionInfections and infestations1/1020/9921/778

Baseline characteristics

Age, Continuous
Age, Continuous(years)TradipitantPlaceboOpen Label TradipitantTotal
Mean49.5 ± 13.9748.8 ± 11.9950.5 ± 12.8450.23 ± 12.88
Sex: Female, Male
Sex: Female, Male(Participants)TradipitantPlaceboOpen Label TradipitantTotal
Female7784617778
Male2515161201
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TradipitantPlaceboOpen Label TradipitantTotal
Hispanic or Latino2922190241
Not Hispanic or Latino7375580728
Unknown or Not Reported02810
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TradipitantPlaceboOpen Label TradipitantTotal
American Indian or Alaska Native101415
Asian0178
Black or African American916155180
Native Hawaiian or Other Pacific Islander0022
White9081589760
Other211114
Region of Enrollment
Region of Enrollment(participants)TradipitantPlaceboOpen Label TradipitantTotal
United States10299778979
08

Study locations

36 sites
  • Vanda Investigational Site
    Birmingham, Alabama 53244, United States
  • Vanda Investigational Site
    Peoria, Arizona 85381, United States
  • Vanda Investigational Site
    Little Rock, Arkansas 72211, United States
  • Vanda Investigational Site
    Chula Vista, California 91910, United States
  • Vanda Investigational Site
    La Jolla, California 92093, United States
  • Vanda Investigational Site
    Los Angeles, California 90010, United States
  • Vanda Investigational Site
    Los Angeles, California 90026, United States
  • Vanda Investigational Site
    Maitland, Florida 32751, United States
  • Vanda Investigational Site
    Palmetto Bay, Florida 33157, United States
  • Vanda Investigational Site
    Tampa, Florida 33613, United States
  • Vanda Investigational Site
    Morrow, Georgia 30260, United States
  • Vanda Investigational Site
    Wauconda, Illinois 60084, United States
  • Vanda Investigational Site
    West Des Moines, Iowa 50265, United States
  • Vanda Investigational Site
    Wichita, Kansas 67214, United States
  • Vanda Investigational Site
    Louisville, Kentucky 40202, United States
  • Vanda Investigational Site
    Marrero, Louisiana 70072, United States
  • Vanda Investigational Site
    Chevy Chase, Maryland 20815, United States
  • Vanda Investigational Site
    Boston, Massachusetts 02114, United States
  • Vanda Investigational Site
    Boston, Massachusetts 02115, United States
  • Vanda Investigational Site
    Chesterfield, Missouri 63005, United States
  • Vanda Investigational Site
    Las Vegas, Nevada 89121, United States
  • Vanda Investigational Site
    Brooklyn, New York 11201, United States
  • Vanda Investigational Site
    Charlotte, North Carolina 28209, United States
  • Vanda Investigational Site
    Raleigh, North Carolina 27612, United States
  • Vanda Investigational Site
    Columbus, Ohio 43214, United States
  • Vanda Investigational Site
    Huber Heights, Ohio 45424, United States
  • Vanda Investigational Site
    Edmond, Oklahoma 73034, United States
  • Vanda Investigational Site
    Tulsa, Oklahoma 74104, United States
  • Vanda Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Vanda Investigational Site
    Chattanooga, Tennessee 37421, United States
  • Vanda Investigational Site
    Nashville, Tennessee 37211, United States
  • Vanda Investigational Site
    Houston, Texas 77043, United States
  • Vanda Investigational Site
    Houston, Texas 77084, United States
  • Vanda Investigational Site
    Plano, Texas 75024, United States
  • Vanda Investigational Site
    San Antonio, Texas 78215, United States
  • Vanda Investigational Site
    Salt Lake City, Utah 84132, United States
09

References and documents

Publications

  • Carlin JL, Polymeropoulos C, Camilleri M, Lembo A, Fisher M, Kupersmith C, Madonick D, Moszczynski P, Smieszek S, Xiao C, Birznieks G, Polymeropoulos MH. The Efficacy of Tradipitant in Patients With Diabetic and Idiopathic Gastroparesis in a Phase 3 Randomized Placebo-Controlled Clinical Trial. Clin Gastroenterol Hepatol. 2024 Dec;22(12):2506-2516. doi: 10.1016/j.cgh.2024.01.005. Epub 2024 Jan 17. PubMed 38237696 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Feb 2025, 66 months.

Results were first posted in Sep 2026, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2019
First posted
Jul 22, 2019
StartActual
Aug 20, 2019
Primary completionActual
Feb 21, 2025
CompletionActual
Feb 21, 2025
Results first posted
Sep 24, 2026
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04028492
Responsible party
Sponsor
First posted
Jul 22, 2019
Start date
Aug 20, 2019
Primary completion
Feb 21, 2025
Completion
Feb 21, 2025
Results posted
Sep 24, 2026
Last update
Sep 24, 2026

Study contacts

Vanda Pharmaceuticals
study director · Vanda Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tradipitant

Start the discussion